NCT06056024 is a Phase 1 clinical trial of BI 3706674 in Solid Tumor, KRAS Mutation, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT06056024?

NCT06056024 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT06056024?

Interventions in NCT06056024: BI 3706674.

What condition does NCT06056024 study?

NCT06056024 studies Solid Tumor, KRAS Mutation.

Is NCT06056024 still recruiting?

NCT06056024 is currently completed. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT06056024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Completed Phase 1 Last updated 17 March 2026

What this trial tests

Phase 1 trial testing BI 3706674 in Solid Tumor, KRAS Mutation in 47 participants. Completed in 17 December 2025.

Timeline

6 December 2023

Primary endpoint
17 December 2025

17 December 2025

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	6 December 2023
Primary completion	17 December 2025
Estimated completion	17 December 2025
Sites	17 locations across Taiwan, Japan, United States, South Korea

Drugs / interventions tested

BI 3706674 — full drug profile →

Conditions studied

Solid Tumor, KRAS Mutation — all drugs for Solid Tumor, KRAS Mutation →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, KRAS Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists. In this study, BI 3706674 is given to humans for the first time. The purpose of this study is to find a suitable dose of BI 3706674 that people with advanced cancer can tolerate when taken alone. Another purpose is to check whether BI 3706674 can make tumours shrink. BI 3706674 blocks growth signals and may prevent the tumour from growing. Participants take BI 3706674 as a tablet when starting treatment. Different doses of BI 3706674 are tested during this study. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting KRAS in cancer.
Singhal A, Li BT, O'Reilly EM. · · 2024 · cited 209× · PMID 38637634 · DOI 10.1038/s41591-024-02903-0
Consensus, debate, and prospective on pancreatic cancer treatments.
Wang J, Yang J, Narang A, He J, et al · · 2024 · cited 56× · PMID 39390609 · DOI 10.1186/s13045-024-01613-x
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.
Yang X, Wu H. · · 2024 · cited 53× · PMID 39522047 · DOI 10.1186/s13045-024-01631-9
Targeting KRAS: from metabolic regulation to cancer treatment.
Shi Y, Zheng H, Wang T, Zhou S, et al · · 2025 · cited 37× · PMID 39799325 · DOI 10.1186/s12943-024-02216-3
"Undruggable KRAS": druggable after all.
Cox AD, Der CJ. · · 2025 · cited 31× · PMID 39638567 · DOI 10.1101/gad.352081.124
Digestive cancers: mechanisms, therapeutics and management.
Zhan T, Betge J, Schulte N, Dreikhausen L, et al · · 2025 · cited 30× · PMID 39809756 · DOI 10.1038/s41392-024-02097-4
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.
Tedeschi A, Schischlik F, Rocchetti F, Popow J, et al · · 2025 · cited 17× · PMID 39711431 · DOI 10.1158/1535-7163.mct-24-0386
Response and Resistance to RAS Inhibition in Cancer.
Ebright RY, Dilly J, Shaw AT, Aguirre AJ. · · 2025 · cited 16× · PMID 40293709 · DOI 10.1158/2159-8290.cd-25-0349

Verify or expand the search:

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06056024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06056024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing